Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present trial is a phase I first in human, double blind, parallel and placebo controlled trial of SSI's adjuvanted chlamydia vaccine CTH522: CTH522-CAF01 (CAF01 is an adjuvant system) and CTH522-Al(OH)3. The trial will be conducted at Imperial College Research site in the United Kingdom.

Subjects are randomly assigned to one of the following three treatment groups in a ratio of 3:3:1.

This trial consisted of 10 visits and 5 telephonic interviews

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity of a Chlamydia Vaccine CTH522

NCT03926728

Trachoma

COMPLETED PHASE1

A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects

NCT03929172

Papillomavirus Infections

COMPLETED PHASE1

Immunogenicity of Fractional Dose of the HPV Vaccines

NCT05291871

HPV Infection HPV Vaccine

ACTIVE_NOT_RECRUITING PHASE4

Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM

NCT00370006

Cytomegalovirus Infection

COMPLETED PHASE1

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

NCT04921111

HPV Infection Vaccine Safety SCT1000

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chlamydia Trachomatis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CTH522-CAF01

CTH522-CAF01: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration (preferably the non-dominant arm)

CTH522 chlamydia antigen diluted with Tris buffer for IN administration

Group Type EXPERIMENTAL

CTH522-CAF01

Intervention Type BIOLOGICAL

CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration

CTH522-Al(OH)3

CTH522-Al(OH)3: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration (preferably the non-dominant arm)

CTH522 chlamydia antigen diluted with Tris buffer for IN administration

Group Type EXPERIMENTAL

CTH522-Al(OH)3

Intervention Type BIOLOGICAL

CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration

Placebo

Saline for IM and In administrations

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTH522-CAF01

CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration

Intervention Type BIOLOGICAL

CTH522-Al(OH)3

CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration

Intervention Type BIOLOGICAL

Placebo

Saline

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Is a healthy female between 18 and 45 years of age on the day of first trial vaccination
2. Has provided signed informed consent
3. Is willing and likely to comply with the trial procedures
4. Is prepared to grant authorised persons access to their medical record
5. Willing to use acceptable contraceptive measures\* during the trial (2 weeks before and 2 weeks after the trial)

* Heterosexually active female capable of becoming pregnant must (in addition to requiring male partner to use condoms) agree to use hormonal contraception, or to complete abstinence, from at least 2 weeks before the first vaccination until at least 2 weeks after the last. (Note: Periodic abstinence \[e.g. calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal and intrauterine device or intrauterine hormone releasing system and progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, are not acceptable methods of contraception)

Exclusion Criteria

1. Has confirmed history of Pelvic Inflammatory Disease or significant gynaecological diseases
2. Is positive for C. trachomatis (PCR)
3. Is positive for gonorrhoea (urine), HIV, Hepatitis B/C, syphilis (blood)
4. Has a positive pregnancy test
5. Has a significant active disease - such as cardiac, liver, immunological, neurological, psychiatric; or clinically significant abnormality of haematological or biochemical parameters.
6. Has BMI of 35 kg/m2 or greater
7. Is currently participating in another clinical trial with an investigational or noninvestigational drug or device
8. Has received, or plans to receive, an active immunisation within 14 days of the start of the trial or any of the immunisation visits in this trial
9. Is currently receiving treatment with immunosuppressive agents e.g. oral, inhaled, nasal or injected corticosteroids. (Topical steroids are allowed, unless applied to the IM injection site.)
10. Is using an intrauterine device
11. Has a condition which in the opinion of the investigator is not suitable for participation in the trial
12. Known or confirmed allergy to any of the vaccine constituents -

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes